<DOC>
	<DOCNO>NCT02388269</DOCNO>
	<brief_summary>A randomized , sham-controlled , single-centre pilot investigation design compare two parallel group , gammaCore®-G ( active treatment ) sham , ( inactive ) treatment subject FGIDs .</brief_summary>
	<brief_title>A Randomized , Single Centre , Double-blind , Parallel , Sham-controlled Pilot Study Using gammaCore®-G</brief_title>
	<detailed_description>This study , subject FGIDs , , randomize , sham-controlled , single-centre pilot investigation design compare two parallel group , gammaCore®-G ( active treatment ) sham , ( inactive ) treatment . The study period begin two-week run-in period , follow four week comparative period subject randomize ( 1:1 ) either active treatment sham ( inactive ) treatment . The comparative period follow open label four week period , subject sham treatment group switch treatment assignment receive active treatment active group continue receive active treatment .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Dyspepsia</mesh_term>
	<criteria>The subject meet follow criterion eligible enter investigation : 1 . Signed Informed Consent Form 2 . Age &gt; 18 3 . Diagnose FD IB Rome III criteria 4 . Is able complete diary , use device follow study procedure 5 . Dyspepsia inclusion criterion , functional dyspepsia accord Rome III Diagnostic Criteria Functional Gastrointestinal Disorders , one following : Bothersome postprandial fullness Early satiation Epigastric pain Epigastric burning No evidence structural disease ( include upper endoscopy ) likely explain symptom * Criteria fulfil last 3 month symptom onset least 6 month prior diagnosis 6 . IBS inclusion criterion , Irritable Bowel Syndrome* accord Rome III Diagnostic Criteria Functional Gastrointestinal Disorders 7 . Recurrent abdominal pain discomfort** least 3 days/month previous 3 month associate two follow : Improvement defecation Onset associate change frequency stool Onset associate change form ( appearance ) stool Criterion fulfil last 3 month symptom onset least 6 month prior diagnosis ** `` Discomfort '' mean uncomfortable sensation describe pain . 8 . In pathophysiology research clinical trial , pain/discomfort frequency least 2 day week screen evaluation recommend subject eligibility . Subjects meet follow criterion permit enter investigation : 1 . Any positive endoscopic finding abnormal biopsy finding and/or abnormal find judged Investigator 2 . Any positive finding sigmoidoscopy colonoscopy diverticulosis , inflammatory bowel disease abnormal find judged Investigator . 3 . Vagotomy location 4 . Has neck lesion ( include lymphadenopathy ) , dysaesthesia , previous surgery abnormal anatomy site gammaCore®G treatment 5 . Has know suspect severe atherosclerotic cardiovascular disease , severe carotid artery disease ( e.g . bruits history transient ischemic attack ( TIA ) cerebral vascular accident CVA ) , congestive heart failure ( CHF ) , know severe coronary artery disease recent ( 5 year ) myocardial infarction 6 . Has abnormal baseline ECG ( e.g . second third degree heart block , atrial fibrillation , atrial flutter , recent history ventricular tachycardia ventricular fibrillation , clinically significant premature ventricular contraction 7 . Has uncontrolled hypertension 8 . Is currently implanted electrical and/or neurostimulator device , include limited cardiac pacemaker defibrillator , vagal neurostimulator , deep brain stimulator , spinal stimulator , bone growth stimulator , gastric stimulator cochlear implant 9 . Has history carotid endarterectomy vascular neck surgery 10 . Has implant metal cervical spine hardware metallic implant near GammaCore®G stimulation site 11 . Has recent ( within 12 month ) repeat history syncope 12 . Has recent ( within 12 month ) repeat history seizure 13 . Has psychiatric cognitive disorder and/or behavioural problem opinion clinician may interfere study 14 . Is pregnant , nursing , think become pregnant study period 15 . Is participate therapeutic clinical investigation participate clinical trial within 30 day period prior study 16 . Is relative employee investigator clinical study site 17 . Used gammaCore®G previously</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>